Gilder Gagnon Howe & Co. LLC Cuts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Gilder Gagnon Howe & Co. LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 3.2% during the fourth quarter, Holdings Channel reports. The firm owned 362,109 shares of the medical equipment provider’s stock after selling 12,052 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Lantheus were worth $22,451,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of LNTH. Braidwell LP increased its stake in shares of Lantheus by 71.7% during the fourth quarter. Braidwell LP now owns 495,100 shares of the medical equipment provider’s stock worth $30,696,000 after buying an additional 206,800 shares during the period. Superstring Capital Management LP purchased a new stake in shares of Lantheus during the fourth quarter worth approximately $3,404,000. Balyasny Asset Management L.P. increased its stake in shares of Lantheus by 8.2% during the fourth quarter. Balyasny Asset Management L.P. now owns 790,649 shares of the medical equipment provider’s stock worth $49,020,000 after buying an additional 60,240 shares during the period. Gabelli Funds LLC increased its stake in shares of Lantheus by 21.3% during the fourth quarter. Gabelli Funds LLC now owns 57,000 shares of the medical equipment provider’s stock worth $3,534,000 after buying an additional 10,000 shares during the period. Finally, Homestead Advisers Corp purchased a new stake in shares of Lantheus during the fourth quarter worth approximately $1,959,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the completion of the transaction, the insider now owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The disclosure for this sale can be found here. Insiders sold a total of 31,928 shares of company stock valued at $2,530,098 over the last three months. 2.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on LNTH shares. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. JMP Securities restated a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. Mizuho increased their price target on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Truist Financial increased their price target on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, B. Riley increased their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $99.17.

View Our Latest Analysis on LNTH

Lantheus Stock Performance

Shares of LNTH stock traded down $0.26 during trading hours on Thursday, hitting $80.19. The stock had a trading volume of 150,084 shares, compared to its average volume of 993,018. The firm has a market capitalization of $5.56 billion, a PE ratio of 12.28 and a beta of 0.56. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $94.47. The stock’s 50 day moving average is $72.74 and its 200 day moving average is $65.31. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55.

Lantheus (NASDAQ:LNTHGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current fiscal year.

Lantheus Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

See Also

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.